Ipsen (IPN.PA) Akcija Цена

Ipsen Цена

Euronext·ZATVORENO
161,60
​
Tržište je zatvoreno

U poslednjih 19 godina prihod Ipsen rastao je 7,9 % godišnje i dostigao 3,68 Млрд EUR. Zarada po akciji rasla je 6,2 % godišnje u poslednjih 19 godina. Za Ipsen neto marža od 12,1 % je pala u odnosu na 23,5 % pre nekoliko godina. Po današnjoj ceni dividendni prinos iznosi otprilike 0,87 %. Odnos isplate je oko 26 % dobiti. Dividenda je rasla 4,6 % godišnje u poslednjih 19 godina. Konsenzusna 12-mesečna ciljana cena za Ipsen je 132,60 EUR, oko ispod kurs za 17,9 %. Od 19 analitičara 8 preporučuje kupovinu — ukupni konsenzus je Drži.

Cena akcije Ipsen

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Ipsen poslovni model i analiza akcije

Ipsen SA je francuska biotehnološka kompanija specijalizovana za razvoj lekova za lečenje raka, neuroloških i endokrinih poremećaja. Osnovao ju je 1929. godine farmaceut Henri Bofo, a sedište se nalazi u Parizu. Istorija kompanije Ipsen počinje proizvodnjom ekstrakata iz zmijevog otrova za izradu serum protiv tetanusa i difterije. Šezdesetih godina prošlog veka, kompanija se fokusirala na proizvodnju hormona i peptida, sa naglaskom na endokrine poremećaje. Tokom devedesetih, Ipsen je proširio svoj portfolijo proizvoda uključujući onkologiju i neurološke poremećaje. Poslovni model Ipsena fokusiran je na istraživanje i razvoj novih lekova, kao i na marketing već etabliranih lekova na odabranim tržištima širom sveta. Kompanija zapošljava oko 5.700 ljudi i posluje u više od 115 zemalja. Ipsen ima dva glavna poslovna segmenta: specijalizovane lekove i potrošačko zdravstvo. Segment specijalizovanih lekova fokusiran je na razvoj i marketing inovativnih terapija u oblastima onkologije, endokrinologije i neurologije. Najpoznatiji proizvodi kompanije Ipsen uključuju Somatuline, lek za lečenje akromegalije, i Decapeptyl, lek za lečenje karcinoma prostate i endometrioze. U segmentu potrošačkog zdravstva, Ipsen je prvenstveno specijalizovan za proizvodnju lekova za lečenje gastrointestinalnih poremećaja i simptoma prehlade i gripe. Neki od poznatih brendova su Smecta, lek za dijareju, i Nurofen, lek protiv bolova. Ipsen takođe ima snažno prisustvo u oblasti estetske medicine, gde kompanija posluje kroz podružnicu pod nazivom Ipsen Aesthetic. Ova podružnica razvija i stavlja na tržište proizvode za lečenje bora i drugih znakova starenja kože. Poznati brendovi Ipsen Aesthetica uključuju Dysport, proizvod na bazi botulinum toksina za lečenje bora, i filer Restylane. U celosti, Ipsen se afirmisao kao vodeća biotehnološka kompanija fokusirana na razvoj i marketing proizvoda u specijalizovanim terapijskim oblastima. Kompanija poseduje snažan pipeline novih proizvoda u razvoju i ostaje važan igrač u farmaceutskoj industriji zahvaljujući svojoj jakoj naučnoj ekspertizi i globalnom prisustvu.

Često postavljana pitanja o akciji Ipsen

Ipsen SA represents values of innovation, integrity, and commitment to improving patient lives. With a strong corporate philosophy centered around patient-focused healthcare solutions, Ipsen SA strives to develop and deliver innovative treatments for complex diseases. The company's dedication to research and development, combined with a global network of partners, allows Ipsen SA to make a positive impact on the lives of patients worldwide.

Ipsen SA's business model revolves around the development, manufacturing, and commercialization of innovative pharmaceutical products for various therapeutic areas. As a global biopharmaceutical company, Ipsen focuses on specialty care and oncology, offering a diverse portfolio of drugs to address unmet medical needs. They aim to improve patients' lives through effective treatments, cutting-edge research, and collaborations with healthcare professionals. Ipsen's commitment to innovation and patient-centric solutions further strengthens their foothold in the pharmaceutical industry.

Ipsen SA is primarily active in the pharmaceutical industry.

The main competitors of Ipsen SA in the market include companies such as Novartis, Sanofi, and Merck KGaA.

Ipsen SA is a renowned pharmaceutical company with a rich history and background. Founded in 1929, Ipsen has grown to become a global leader in specialty care treatments for urology, oncology, and endocrinology. With a strong focus on innovation and research, Ipsen has developed a diverse range of products to address various medical needs. Over the years, the company has expanded its reach to more than 115 countries and collaborates with numerous partners to enhance patient care worldwide. Ipsen's commitment to improving patient outcomes through cutting-edge therapies and its global presence has solidified its position as a trusted name in the pharmaceutical industry.

Some significant milestones achieved by Ipsen SA include the acquisition of Clementia Pharmaceuticals in 2019, expanding its rare diseases portfolio, and the FDA approval of Cabometyx for advanced hepatocellular carcinoma in 2018. Ipsen SA has also made advancements in neurology, with the 2019 FDA approval of Dysport for pediatric lower limb spasticity. Furthermore, Ipsen SA has collaborated with partners to develop innovative treatments, such as the partnership with Exelixis for the development of Cabometyx. These milestones highlight Ipsen SA's commitment to research, development, and expanding treatment options in various therapeutic areas.

Ipsen SA is primarily present in various countries and regions globally. The company has a strong presence in Europe, with its headquarters based in France. Ipsen also has significant operations in the United States and several other countries across North and South America, including Canada and Brazil. Additionally, Ipsen has a growing presence in Asia, particularly in China and Japan, as well as key markets in the Middle East and Africa. With its widespread footprint, Ipsen SA aims to serve patients and healthcare professionals across multiple regions and provide its pharmaceutical solutions to a diverse and global community.

Analitičari trenutno postavljaju prosečnu ciljanu cenu 135,82 EUR za akciju Ipsen (medijana: 132,60 EUR), što znači -16,4 % u odnosu na poslednju cenu. Konsenzus se zasniva na 19 ocena.

19 analitičara trenutno ocenjuje akciju Ipsen: 8 preporučuje kupovinu, 9 držanje i 2 prodaju. Za 2026 analitičari očekuju da Ipsen ostvari prihod 4,63 Млрд EUR i zaradu po akciji 16,35 EUR.

Akcija Ipsen (IPN.PA) kotira na 8 berze, uključujući: London (0MH6.L), Frankfurt (I7G.F), München (I7G.MU), Düsseldorf (I7G.DU), Wien (IPN.VI), Paris (IPN.PA).

Ipsen SA is a global pharmaceutical company based in Paris, France. The company specializes in the research, development, manufacturing, and marketing of medications used to treat cancer, neurological diseases, and rare diseases. Ipsen offers a wide range of products divided into three main business areas. 1. Oncology In the field of oncology, Ipsen offers therapies for the treatment of neuroendocrine tumors (NET), prostate cancer, and pancreatic cancer. The company also has a promising pipeline of medications for the treatment of various types of cancer. 2. Neuroscience Ipsen is a leading provider of therapies for the treatment of neurological diseases such as spasticity, cerebral palsy, and migraines. Products in this area include Dysport, an injectable botulinum toxin, as well as numerous other orally-administered medications. 3. Rare Diseases Ipsen has also specialized in the development and marketing of therapies for the treatment of rare diseases. Products in this area include Somatuline for the treatment of acromegaly and neuroendocrine tumors, as well as Increlex for the treatment of short stature. In addition, Ipsen has a strong presence in Europe, North America, and the Asia-Pacific region. The company has built a large network of subsidiaries, distribution partners, and licensees that allows it to market its products worldwide. Ipsen also relies on innovative partnerships and strategic acquisitions to strengthen its market presence. In 2020, the company acquired Clementia Pharmaceuticals, a company specializing in the development of therapies for the treatment of rare bone diseases such as fibrodysplasia ossificans progressiva (FOP). Overall, Ipsen's business model is based on a strong research and development department that focuses on identifying new therapies and improving existing treatment options. The company works closely with medical professionals, academic institutions, and other industry partners. Ipsen also strives for sustainable corporate development by focusing on environmentally-friendly practices and ethical business practices. The company is committed to carbon-neutral production and supports social projects worldwide. Overall, Ipsen has built a robust business model supported by its strong presence in the global market, its products in various therapy areas, and its innovative research and development department.

očekivana prihod od Ipsen je 4,63 Млрд EUR. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od Ipsen je 1,34 Млрд EUR. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Ipsen je trenutno 9,88. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Ipsen.

Odnos cene i prihoda (KUV) za Ipsen je trenutno 2,87. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Ipsen.

Eulpool score kvaliteta za Ipsen je 6/10.

ISIN za Ipsen je FR0010259150. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Ipsen je A0ESMG. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Ipsen je IPN.PA. Simbol tikera se koristi za trgovinu akcijama Ipsen na berzanskom tržištu.

Фер вредностTerminal
168,06 EUR
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Фармацеутски производи
Број акција
Запослени
Приход по запосленом
633.011,88 EUR
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт ipsen.com
Валута
EUR
Јавна понуда
6. дец 2005.
ISIN
FR0010259150
CUSIP
F5362H107
SEDOL
B0R7JF1
Тржишна капитализација
Опсег од 52 недеље
AAQS
6 / 10
PEG
-16,87
P/E однос
P/Ee 2026
10,02
P/Ee 2027
11,18
P/Ee 2028
12,17
P/Ee 2029
11,38
P/Ee 2030
10,96
P/S
P/Se
2,87
EV/EBIT
17,17
P/B однос
3,11
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
8,54 %
Дивиденда
Прinos од дивиденде
0,87 %
Процењени принос од дивиденде
0,99 %
Стопа исплате
25,89 %
Раст дивиденде Ø5Y
5,92 %
Дивиденде по години
1
Дивиденда исплаћена од
20 година
Дивиденда није смањена од
20 година
Дивиденда повећана од
1 година
Порез на дивиденде
25,00 %
Zadnje ažurirano 21. нов 2026. 11:09

Ipsen Тикер

DISELORF · I7G.DUEURONEXT · IPN.PAFRANKFURT · I7G.FLONDON · 0MH6.LMINHEN · I7G.MUPARIZ · IPN.PAOTC · IPSEFBEČ · IPN.VI

Ipsen FIGI

IPN:FP · BBG000BWH999I7G:GR · BBG000FTWK18I7G:GF · BBG000FTWKD5I7G:GD · BBG000FTXMC1I7G:GS · BBG000FTXNL9I7G:GM · BBG000FTXP70I7G:GB · BBG000FTXPS7IPSEF:US · BBG000GNNSP7IPSEF:UV · BBG000GNP2P2IPNUSD:EO · BBG000HFL4J5IPNUSD:E1 · BBG000HFLKV5IPNUSD:XT · BBG000HFLLJ7

Sve ključne metrke i detaljne analize Ipsen u dubinskoj analizi

Naša analiza akcija za akciju Ipsen uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Ipsen. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: